Patents by Inventor Nathaniel C. Lallatin

Nathaniel C. Lallatin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies to human thymidine kinase to treat cancer
    Patent number: 8551486
    Abstract: A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: October 8, 2013
    Assignee: Savoy Pharmaceuticals, Inc.
    Inventor: Nathaniel C. Lallatin
  • MONOCLONAL ANTIBODIES TO HUMAN THYMIDINE KINASE TO TREAT CANCER
    Publication number: 20100143244
    Abstract: A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired.
    Type: Application
    Filed: December 4, 2008
    Publication date: June 10, 2010
    Inventor: Nathaniel C. Lallatin
  • MONOCLONAL ANTIBODIES TO HUMAN THYMIDINE KINASE TO TREAT CANCER
    Publication number: 20100143290
    Abstract: A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired.
    Type: Application
    Filed: December 2, 2009
    Publication date: June 10, 2010
    Inventor: Nathaniel C. Lallatin